Appendix to:

**Frequency of biologically-defined AD in relation to age, sex, APOEε4 and cognitive impairment in a prospective cohort study**

Joseph Therriault BSc1,2,3, Tharick A. Pascoal MD PhD1,2,3, Andrea L. Benedet PhD1,2,3, Cecile Tissot BSc1,2,3, Melissa Savard MSc1, Mira Chamoun PhD1,2, Firoza Lussier BSc1,2,3, Min Su Kang BSc1,2,3, Gleb Berzgin PhD1,2,3, Tina Wang MSc1,2,3, Jaime Fernandes-Arias MSc1,2,3, Gassan Massarweh PhD3,5, Jean-Paul Soucy MD MSc2,3, Paolo Vitali MD PhD2, Paramita Saha-Chaudhuri PhD6, Serge Gauthier MD, FRCPC1,2,4, and Pedro Rosa-Neto MD, PhD\*1,2,3,4

1Translational Neuroimaging Laboratory, The McGill University Research Centre for Studies in Aging, Douglas Hospital, McGill University, Montreal, Canada.

2Department of Neurology and Neurosurgery, McGill University, Montreal, Canada.

3Montreal Neurological Institute, Montreal, Canada.

4Department of Psychiatry, McGill University, Montreal, Canada

5Department of Radiochemistry, McGill University, Montreal, Canada

6Department of Epidemiology and Biostatistics, McGill University, Montreal, Canada

**List of supplementary material:**

Supplementary Tables:

Supplementary Table 1: Clinical + demographic data of CU young individuals

Supplementary Table 2: A/T biomarker classification in atypical AD phenotypes

Supplementary Tables 3-6: Full model statistics for frequency analyses

Supplementary Figures:

Supplementary Figure 1: Contingency table of tau classification (Braak vs meta-ROI)

Supplementary Figure 2: Association between A/T/N status and clinical impairment

Supplementary Figure 3: Frequency of AD biomarkers according to age and clinical impairment

Supplementary Figure 4: Association between A/T/N status and age, APOE4 and sex

Supplementary Figure 5: Clinical-biological discordance stratified by age

Supplementary Figure 6: A/T/N status by diagnosis

Supplementary Figure 7: AD biomarker status according to CDR when tau positivity is defined in Braak I-II ROIs.

Supplementary Figure 8: AD biomarker status according to APOE4 and sex when when tau positivity is defined using Braak I-II ROIs

Supplementary Figure 9: Biological AD spectrum entities in relation to clinical diagnosis when defining tau-positivity with Braak I-II ROIs

Supplementary Figure 10: Stability of tau-PET threshold